According to a new analysis from Future Market Insights, the potassium formate market is on a steady upward trajectory, projected to cross USD 950 million by 2033, with a consistent CAGR of 4.5% over ...

Demand for potassium sorbate is on track to experience a steady rise, with its industry value estimated to reach USD 69.8 ...

Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution. Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2021. United States Drug Enforcement Agency.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced late-breaking Phase 4 data evaluating treatment benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in ...

Sodium sulfate, potassium sulfate and magnesium sulfate oral solution 17.5 g/3.13g/1.6g are available in a cartons of two 6-oz. bottles.

About Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...

References: Xywav (calcium, magnesium, potassium and sodium oxybates) oral solution. Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2021. United States Drug Enforcement Agency.

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL.

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately ...

Scienture LLC’s product candidate SCN-102, (Losartan Oral Suspension 10mg/mL), is a ready to use oral suspension of Losartan for increased patient convenience and ease of dosing.